This HTML5 document contains 231 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n27http://linked.opendata.cz/resource/AHFS/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/wikipedia/
n23http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n30http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/pdb/
n28http://linked.opendata.cz/resource/drugbank/mixture/
n19http://www.drugs.com/
n25http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n20http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
n24http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00641/identifier/chebi/
n29http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00641
rdf:type
n3:Drug
n3:description
Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL receptors, it increases breakdown of LDL cholesterol. [PubChem]
n3:dosage
n30:271B5F01-363D-11E5-9242-09173F13E4C5 n30:271B5F02-363D-11E5-9242-09173F13E4C5 n30:271B5F03-363D-11E5-9242-09173F13E4C5 n30:271B5F04-363D-11E5-9242-09173F13E4C5 n30:271B5F05-363D-11E5-9242-09173F13E4C5 n30:271B5F06-363D-11E5-9242-09173F13E4C5 n30:271B5F07-363D-11E5-9242-09173F13E4C5 n30:271B5F08-363D-11E5-9242-09173F13E4C5 n30:271B5F09-363D-11E5-9242-09173F13E4C5 n30:271B5F0A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007 Jul 19;5:20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17640385
n3:group
approved
n3:halfLife
3 hours
n3:indication
For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia.
n3:manufacturer
n4:271B5EBF-363D-11E5-9242-09173F13E4C5 n4:271B5EC0-363D-11E5-9242-09173F13E4C5 n4:271B5EBD-363D-11E5-9242-09173F13E4C5 n4:271B5EBE-363D-11E5-9242-09173F13E4C5 n4:271B5EB3-363D-11E5-9242-09173F13E4C5 n4:271B5EB4-363D-11E5-9242-09173F13E4C5 n4:271B5EBB-363D-11E5-9242-09173F13E4C5 n4:271B5EBC-363D-11E5-9242-09173F13E4C5 n4:271B5EB9-363D-11E5-9242-09173F13E4C5 n4:271B5EBA-363D-11E5-9242-09173F13E4C5 n4:271B5EB7-363D-11E5-9242-09173F13E4C5 n4:271B5EB8-363D-11E5-9242-09173F13E4C5 n4:271B5EB5-363D-11E5-9242-09173F13E4C5 n4:271B5EB6-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00641 n25:DB00641
dcterms:title
Simvastatin
adms:identifier
n10:PA451363 n13:16714-681-01 n14:SIM n15:D00434 n16:9150 n17:DB00641 n21:Simvastatin
n3:mechanismOfAction
Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed <i>in vivo</i> to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol.
n3:packager
n4:271B5E94-363D-11E5-9242-09173F13E4C5 n4:271B5E9F-363D-11E5-9242-09173F13E4C5 n4:271B5E78-363D-11E5-9242-09173F13E4C5 n4:271B5E79-363D-11E5-9242-09173F13E4C5 n4:271B5E76-363D-11E5-9242-09173F13E4C5 n4:271B5E77-363D-11E5-9242-09173F13E4C5 n4:271B5E7C-363D-11E5-9242-09173F13E4C5 n4:271B5E7D-363D-11E5-9242-09173F13E4C5 n4:271B5E7A-363D-11E5-9242-09173F13E4C5 n4:271B5E7B-363D-11E5-9242-09173F13E4C5 n4:271B5E74-363D-11E5-9242-09173F13E4C5 n4:271B5E75-363D-11E5-9242-09173F13E4C5 n4:271B5E72-363D-11E5-9242-09173F13E4C5 n4:271B5E73-363D-11E5-9242-09173F13E4C5 n4:271B5E89-363D-11E5-9242-09173F13E4C5 n4:271B5E8A-363D-11E5-9242-09173F13E4C5 n4:271B5E86-363D-11E5-9242-09173F13E4C5 n4:271B5E87-363D-11E5-9242-09173F13E4C5 n4:271B5E8D-363D-11E5-9242-09173F13E4C5 n4:271B5E8E-363D-11E5-9242-09173F13E4C5 n4:271B5E8B-363D-11E5-9242-09173F13E4C5 n4:271B5E8C-363D-11E5-9242-09173F13E4C5 n4:271B5E80-363D-11E5-9242-09173F13E4C5 n4:271B5E81-363D-11E5-9242-09173F13E4C5 n4:271B5E7E-363D-11E5-9242-09173F13E4C5 n4:271B5E7F-363D-11E5-9242-09173F13E4C5 n4:271B5E84-363D-11E5-9242-09173F13E4C5 n4:271B5E85-363D-11E5-9242-09173F13E4C5 n4:271B5E82-363D-11E5-9242-09173F13E4C5 n4:271B5E83-363D-11E5-9242-09173F13E4C5 n4:271B5EAF-363D-11E5-9242-09173F13E4C5 n4:271B5EB0-363D-11E5-9242-09173F13E4C5 n4:271B5EAD-363D-11E5-9242-09173F13E4C5 n4:271B5EAE-363D-11E5-9242-09173F13E4C5 n4:271B5EB1-363D-11E5-9242-09173F13E4C5 n4:271B5EB2-363D-11E5-9242-09173F13E4C5 n4:271B5EA7-363D-11E5-9242-09173F13E4C5 n4:271B5EA8-363D-11E5-9242-09173F13E4C5 n4:271B5EA5-363D-11E5-9242-09173F13E4C5 n4:271B5EA6-363D-11E5-9242-09173F13E4C5 n4:271B5EAB-363D-11E5-9242-09173F13E4C5 n4:271B5EAC-363D-11E5-9242-09173F13E4C5 n4:271B5EA9-363D-11E5-9242-09173F13E4C5 n4:271B5EAA-363D-11E5-9242-09173F13E4C5 n4:271B5EA0-363D-11E5-9242-09173F13E4C5 n4:271B5EA3-363D-11E5-9242-09173F13E4C5 n4:271B5EA4-363D-11E5-9242-09173F13E4C5 n4:271B5EA1-363D-11E5-9242-09173F13E4C5 n4:271B5EA2-363D-11E5-9242-09173F13E4C5 n4:271B5E88-363D-11E5-9242-09173F13E4C5 n4:271B5E99-363D-11E5-9242-09173F13E4C5 n4:271B5E9A-363D-11E5-9242-09173F13E4C5 n4:271B5E97-363D-11E5-9242-09173F13E4C5 n4:271B5E98-363D-11E5-9242-09173F13E4C5 n4:271B5E9D-363D-11E5-9242-09173F13E4C5 n4:271B5E9E-363D-11E5-9242-09173F13E4C5 n4:271B5E9B-363D-11E5-9242-09173F13E4C5 n4:271B5E9C-363D-11E5-9242-09173F13E4C5 n4:271B5E91-363D-11E5-9242-09173F13E4C5 n4:271B5E92-363D-11E5-9242-09173F13E4C5 n4:271B5E8F-363D-11E5-9242-09173F13E4C5 n4:271B5E90-363D-11E5-9242-09173F13E4C5 n4:271B5E95-363D-11E5-9242-09173F13E4C5 n4:271B5E96-363D-11E5-9242-09173F13E4C5 n4:271B5E93-363D-11E5-9242-09173F13E4C5
n3:patent
n7:5846966 n7:RE37721
n3:routeOfElimination
Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.
n3:synonym
Synvinolin Zocor Simvastatin Simvastatinum MK-733 Simvastatina 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one Simvastatine
n3:toxicity
The most common adverse reactions that lead to discontinuation of therapy include gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%).
n3:volumeOfDistribution
Simvastatin can cross the blood-brain-barrier.
n26:hasAHFSCode
n27:24-06-08
n3:foodInteraction
Avoid alcohol. Avoid drastic changes in dietary habit. Avoid taking with grapefruit juice.
n3:mixture
n28:271B5E71-363D-11E5-9242-09173F13E4C5 n28:271B5E6F-363D-11E5-9242-09173F13E4C5 n28:271B5E70-363D-11E5-9242-09173F13E4C5 n28:271B5E6E-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Both simvastatin and its β-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins.
n3:synthesisReference
Shieh-Shung J. Chen, Byron H. Arison, "Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs." U.S. Patent US4965200, issued April, 1981.
n22:hasConcept
n23:M0029425
foaf:page
n19:simvastatin.html n20:simva.htm n24:zoc1500.shtml
n3:IUPAC-Name
n8:271B5F0F-363D-11E5-9242-09173F13E4C5
n3:InChI
n8:271B5F15-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n8:271B5F14-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n8:271B5F11-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n8:271B5F12-363D-11E5-9242-09173F13E4C5
n3:SMILES
n8:271B5F13-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n8:271B5F25-363D-11E5-9242-09173F13E4C5 n8:271B5F0D-363D-11E5-9242-09173F13E4C5
n3:logP
n8:271B5F27-363D-11E5-9242-09173F13E4C5 n8:271B5F0B-363D-11E5-9242-09173F13E4C5 n8:271B5F0E-363D-11E5-9242-09173F13E4C5
n3:logS
n8:271B5F0C-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n29:C10AA01
n3:H-Bond-Acceptor-Count
n8:271B5F1B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n8:271B5F1C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n8:271B5F16-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n8:271B5F17-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n8:271B5F19-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n8:271B5F18-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n8:271B5F1A-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the availability of the drug in the systemic is low. Peak plasma concentration occurs 1.3 - 2.4 hours after administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
79902-63-9
n3:category
n3:containedIn
n6:271B5EF3-363D-11E5-9242-09173F13E4C5 n6:271B5EF4-363D-11E5-9242-09173F13E4C5 n6:271B5EF1-363D-11E5-9242-09173F13E4C5 n6:271B5EF2-363D-11E5-9242-09173F13E4C5 n6:271B5EF7-363D-11E5-9242-09173F13E4C5 n6:271B5EF8-363D-11E5-9242-09173F13E4C5 n6:271B5EF5-363D-11E5-9242-09173F13E4C5 n6:271B5EF6-363D-11E5-9242-09173F13E4C5 n6:271B5EEB-363D-11E5-9242-09173F13E4C5 n6:271B5EEC-363D-11E5-9242-09173F13E4C5 n6:271B5EE9-363D-11E5-9242-09173F13E4C5 n6:271B5EEA-363D-11E5-9242-09173F13E4C5 n6:271B5EEF-363D-11E5-9242-09173F13E4C5 n6:271B5EF0-363D-11E5-9242-09173F13E4C5 n6:271B5EED-363D-11E5-9242-09173F13E4C5 n6:271B5EEE-363D-11E5-9242-09173F13E4C5 n6:271B5EFB-363D-11E5-9242-09173F13E4C5 n6:271B5EFC-363D-11E5-9242-09173F13E4C5 n6:271B5EF9-363D-11E5-9242-09173F13E4C5 n6:271B5EFA-363D-11E5-9242-09173F13E4C5 n6:271B5EFF-363D-11E5-9242-09173F13E4C5 n6:271B5F00-363D-11E5-9242-09173F13E4C5 n6:271B5EFD-363D-11E5-9242-09173F13E4C5 n6:271B5EFE-363D-11E5-9242-09173F13E4C5 n6:271B5ED1-363D-11E5-9242-09173F13E4C5 n6:271B5ED2-363D-11E5-9242-09173F13E4C5 n6:271B5ED0-363D-11E5-9242-09173F13E4C5 n6:271B5ED3-363D-11E5-9242-09173F13E4C5 n6:271B5ED4-363D-11E5-9242-09173F13E4C5 n6:271B5ECE-363D-11E5-9242-09173F13E4C5 n6:271B5ECF-363D-11E5-9242-09173F13E4C5 n6:271B5ED7-363D-11E5-9242-09173F13E4C5 n6:271B5ED8-363D-11E5-9242-09173F13E4C5 n6:271B5ED5-363D-11E5-9242-09173F13E4C5 n6:271B5ED6-363D-11E5-9242-09173F13E4C5 n6:271B5EC8-363D-11E5-9242-09173F13E4C5 n6:271B5EC9-363D-11E5-9242-09173F13E4C5 n6:271B5EC6-363D-11E5-9242-09173F13E4C5 n6:271B5EC7-363D-11E5-9242-09173F13E4C5 n6:271B5ECC-363D-11E5-9242-09173F13E4C5 n6:271B5ECD-363D-11E5-9242-09173F13E4C5 n6:271B5ECA-363D-11E5-9242-09173F13E4C5 n6:271B5ECB-363D-11E5-9242-09173F13E4C5 n6:271B5EE3-363D-11E5-9242-09173F13E4C5 n6:271B5EE4-363D-11E5-9242-09173F13E4C5 n6:271B5EE1-363D-11E5-9242-09173F13E4C5 n6:271B5EE2-363D-11E5-9242-09173F13E4C5 n6:271B5EE7-363D-11E5-9242-09173F13E4C5 n6:271B5EE8-363D-11E5-9242-09173F13E4C5 n6:271B5EE5-363D-11E5-9242-09173F13E4C5 n6:271B5EE6-363D-11E5-9242-09173F13E4C5 n6:271B5EDB-363D-11E5-9242-09173F13E4C5 n6:271B5EDC-363D-11E5-9242-09173F13E4C5 n6:271B5ED9-363D-11E5-9242-09173F13E4C5 n6:271B5EDA-363D-11E5-9242-09173F13E4C5 n6:271B5EDF-363D-11E5-9242-09173F13E4C5 n6:271B5EE0-363D-11E5-9242-09173F13E4C5 n6:271B5EDD-363D-11E5-9242-09173F13E4C5 n6:271B5EDE-363D-11E5-9242-09173F13E4C5 n6:271B5EC1-363D-11E5-9242-09173F13E4C5 n6:271B5EC4-363D-11E5-9242-09173F13E4C5 n6:271B5EC5-363D-11E5-9242-09173F13E4C5 n6:271B5EC2-363D-11E5-9242-09173F13E4C5 n6:271B5EC3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n8:271B5F21-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n8:271B5F23-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n8:271B5F24-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n8:271B5F26-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n8:271B5F20-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n8:271B5F1F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n8:271B5F22-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n8:271B5F10-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n8:271B5F1D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n8:271B5F1E-363D-11E5-9242-09173F13E4C5